Key points from article :
Strategies to prevent, mitigate, reverse cancer, treatment-related ageing consequences, discussed.
Emphasis placed on therapies linked to age-related conditions or hallmarks of ageing.
That could be potential targets for interventions, focusing on cellular senescence.
Senescent cells are a target for ageing interventions, because they do not divide.
Rapamycin, a promising agent that has been implicated in both ageing and senescence.
When fed to older mice, it was shown to delay ageing and extend lifespan.
Senolytics have also achieved success in recent pre-clinical studies.
Open-label study of dasatinib plus quercetin for idiopathic pulmonary fibrosis, recently published.
After 9 doses over 3 weeks, participants showed improved physical function 1 week later.
mTOR inhibitors, senolytics, to be tested as preventatives of age-related conditions in cancer.
Initiative by National Cancer Institute, published in the Journal of the National Cancer Institute.
